Podcasts about wclc

In this episode, recorded live in Spanish at WCLC 2025, Dr. Diego Carrillo reflects on his experiences as a junior faculty member at WCLC 2025. In conversation with host Dr. Narjust Florez, they discuss conference activities, research highlights, and how WCLC helps junior faculty build their networks and shape the future of lung cancer care and research.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.

JCO fellow Dr. Ece Cali speaks with JCO Associate Editor Dr. Thomas E. Stinchcombe to discuss the JCO article "Phase 2 Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)", that was simultaneously released at the IASLC 2025 World Conference on Lung Cancer. TRANSCRIPT Dr. Ece Cali: Hello, and welcome to our series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's most important oncology meetings. I am your host, Dr. Ece Cali, JCO editorial fellow, and I am joined by Dr. Tom Stinchcombe, JCO associate editor, to discuss the Journal of Clinical Oncology article and 2025 World Conference on Lung Cancer abstract presentation, “Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations.” The WU-KONG1B trial is a multinational, phase II study that investigated the efficacy and safety of different doses of sunvozertinib in patients with metastatic non-small cell lung cancer and EGFR exon 20 insertion mutations after progression on platinum based chemotherapy. Tom, before we dive into the results, could you walk us through the rationale for this study, and how does it fit into the current treatment options for patients with EGFR exon 20 insertion? Dr. Tom Stinchcombe: Thank you, Dr. Cali. I think the clinical context is always important. We have known that EGFR exon 20 insertions exist and that they are resistant to our currently available EGFR tyrosine kinase inhibitors, and I think there have been attempts in the past to develop a tyrosine kinase inhibitor, but there is a very narrow therapeutic window between the dose you need to inhibit the EGFR mutation in the cancer and the EGFR receptor on normal tissues, most notably the mucosa, the gut, and the skin. And so, our previous attempts have failed largely because the dose required was not tolerable for patients and they could not really stay on the drug for a long time or they were not very active. And so, I think there was a real desire to develop an EGFR tyrosine kinase inhibitor, and then, historically, the standard had been a platinum based doublet as the standard of care. And more recently, platinum based doublet with amivantamab has proven to be superior to platinum based chemotherapy alone. I think the context is also important that amivantamab is not necessarily available in all the countries, and so, there are patients who do not have access to amivantamab. Going to the rationale, I think that this drug had shown preliminary promise of having activity but without that being encumbered by those EGFR wild type toxicities, and, therefore, it was really explored in this larger study. Dr. Ece Cali: And what are some key findings from this trial? Dr. Tom Stinchcombe: So, I think that we should look at the study design. It is a little quirky, for lack of a better term, in that there is a randomization to 200 versus 300 mg, and then, there was a nonrandomized cohort of 300 mg. So, when you look at the study, if you are a purist, you will just look at the randomized patients. If you are sort of an aggregator, you look at all patients. So, it shows reporting on three cohorts, but I think the key findings are that the 200 mg and the 300 mg treatments had similar toxicities in terms of response rate, duration of response, and progression free survival. And as you know going through the review, there was a lot of queries from the reviewers as to which would be the preferred dose, and to me, I think this really illustrates a dose finding component to a trial design because there is a lot of debate about what the minimal effective dose is or the optimal dose. And in this case, having the two dose cohorts did provide us some valuable efficacy and toxicity information. And then, when I look at the study, I want to make sure it reflects my patient population, and about a quarter of patients had brain metastases, and about 15% had previous amivantamab, and about 5% to 10% had another EGFR tyrosine kinase inhibitor. Dr. Ece Cali: And what is the objective response rate and the duration of response? These are pretty good numbers for this patient population. Dr. Tom Stinchcombe: In the 200 mg cohort, it was about 46%. The duration of response was around 11 months, and the PFS was around 8 months. The 300 mg cohort was 46%, duration of response 9.8, and the median PFS is 6.9 months, and I think that this is greater activity than we have seen with our previous attempts at EGFR tyrosine kinase inhibitors. Dr. Ece Cali: And based on these data, FDA granted accelerated approval for sunvozertinib very recently at 200 mg once daily dosing in this setting. So, that is a major step forward for our patients. Dr. Stinchcombe, how does this impact your clinical practice, and what side effects should oncologists be watching for if they prescribe this medication? Dr. Tom Stinchcombe: So, I think it was very interesting that they chose the 200 mg dose, which I think was more tolerable, and when we kind of look at this, there still was a rate of diarrhea, all grade, rash, paronychia, which are the EGFR related toxicities. There can be some decreased appetite, stomatitis, and then, it can lead to some lab abnormalities, like increased CPK and creatinine that physicians have to be aware of. You know, how it will affect my practice is that all these patients had received a platinum based chemotherapy as the first line therapy. I think that this would become my preferred second line therapy for patients outside the context of a trial because of the activity and the tolerability. Dr. Ece Cali: And lastly, several other tyrosine kinase inhibitors are being evaluated for EGFR exon 20 insertion, including in the frontline setting. So, what are some of the outstanding questions in this space, and what data should our listeners keep an eye on moving forward? Dr. Tom Stinchcombe: I think you are right that now, there is going to be another EGFR tyrosine kinase that may become available in the next year, and there is another drug, furmonertinib, that is being investigated. I think, for the clinical question, is, well, can we move these into the first line setting? And actually, the development path has two ways of doing this. There is EGFR tyrosine kinase compared to platinum based chemotherapy, and then, platinum based chemotherapy with an EGFR tyrosine kinase versus platinum based chemotherapy, and both have their merits and strengths. And so, I think it is going to be very interesting as we see if those first line trials, one, can they be demonstrated to be superior to platinum based chemotherapy, and then by what magnitude and what the side effects are. But I think we are hoping that in the next couple of years, we will have an additional first line option for our patients. Dr. Ece Cali: Yeah, it is always great to have more options for our patients. Thank you, Dr. Stinchcombe, for speaking about the JCO article, “Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations.” Join us again for the latest JCO simultaneous publications. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of World Lung Conference. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.

In this episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu share tips for first-time attendees of the World Conference on Lung Cancer (WCLC). Recorded live at WCLC 2025, hear their 10 key recommendations to make the most of your experience, including advice on how to sneak self-care into your busy conference schedule.

Featuring an interview with Dr Jacob Sands, including the following topics: TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00) Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52) Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599. Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500. Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26) Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11. CME information and select publications

IASLC_WCLC 2025 Preview by IASLC

The 2024 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Sally Lau moderates a discussion in Cantonese Chinese about highlights from the conference with Dr. David Lee and Dr. Molly Li.

In this week's podcast, we explore the critical links between environmental factors and lung cancer risk, focusing on the impacts... The post Climate Change and Other Environmental Factors on Lung Cancer Risk at WCLC 2024 appeared first on VJOncology.

In this episode, Dr. Paul Wheatley-Price chats with Dr. Peter Ellis, Thoracic Medical Oncologist at the Juravinski Cancer Center and Professor at McMaster University about the highlights at this year's annual World Conference of Lung Cancer in San Diego and European Society of Medical Oncology Conference in Barcelona. Some very exciting updates with immunotherapy in early and advanced lung cancers, and the patient perspectives on clinical trials!

At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate.  In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.    To learn more about the topic in this episode:  iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer 'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field See omnystudio.com/listener for privacy information.

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Fawzi Abu Rous, Dr. Raid Aljumaily, Dr. Abdulaziz AlJassim, and Dr. Ashraf Mohamed. Host: Dr. Nagla Abdel Karim Thoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer Institute Professor of Medicine at the University of Virginia School of Medicine Guests: Dr. Fawzi Abu Rous Thoracic Medical Oncologist Henry Ford Health, Detroit, MI Dr. Raid Aljumaily Associate Professor of Medicine University of Oklahoma Dr. Abdulaziz AlJassim Senior Specialist in Thoracic Medical Oncology and Internal Medicine. Kuwait Cancer Control Center, Kuwait Dr. Ashraf Mohamed Director of Surgery Business Development Siemens Healthineers

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, Chief of Medical Oncology at the Sylvester Comprehensive Cancer Center, to discuss the highlights from the World Conference on Lung Cancer 2024. Join us as we dive into four key studies that could reshape our understanding and approach to lung cancer treatment: 1. Checkmate 816 vs. Checkmate 77T: An exploratory analysis of neoadjuvant chemoimmunotherapy and the ongoing debate about the benefits of post-operative immunotherapy. 2. SKIPPirr Study: Discover how prophylactic strategies can reduce infusion-related reactions with amivantamab. 3. HARMONi-2: A look at a novel PD-1 and VEGF inhibitor compared to Pembrolizumab in metastatic non-small cell lung cancer. 4. TROPION-Lung01: Insights into the performance of the antibody-drug conjugate Dato-DXd against docetaxel, particularly in non-squamous histology. Tune in for an informative discussion that highlights the latest advancements in lung cancer research and treatment strategies. Don't forget to like, subscribe, and check out our other episodes for more insights into the current standard of care in oncology! #OncologyBrothers #LungCancer #WCLC2024 #CancerResearch #MedicalOncology   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Isabella Favato Barcelos and Dr. William Nassib William. Guests: Dr. Clarissa Mathias Medical Oncologist at Oncoclinicas Bahia and Hospital Santa Izabel Dr. Isabella Favato Barcelos Medical Oncologist, Oncoclinicas&Co/MedSir, Brazil Dr. William Nassib William National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

In this special episode of Lung Cancer Considered, Stephanie McDonald and Jillian Thompson discuss their perspectives of attending the 2024 World Conference on Lung Cancer as nurse practitioners. Hear their favorite sessions, their observations as first-time attendees, and why they hope to see more nurse practitioners at future IASLC events. Guests: Jillian Thompson, MSN, ANP-BC, AOCNP Nurse Practitioner MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center Stephanie McDonald RN, MSN, FNP-BC, AOCNP Nurse Practitioner Dana-Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Coral Olazagasti moderates a discussion in Spanish about highlights from the conference with Dr. Maria Velez and Dr. Rossana Ruiz. Guests: Dr. Coral Olazagasti Assistant Professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Rossana Ruiz Medical Oncologist from Universidad Peruana Cayetano Heredia Global Health Fellowship at MGH in Boston, Massachusetts Thoracic Medical Oncologist, Instituto Nacional de Enfermedades Neoplasicas and AUNA-Oncosalud in Lima, Peru Dr. Maria Velez Clinical Instructor, Division of Hematology-Oncology UCLA David Geffen School of Medicine in Los Angeles, California

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research. Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain. Guests: Dr. Hidehito Horinouchi Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo General Secretary, Japan Clinical Oncology Group Dr. Noemi Reguart Clinical Professor at the University of Barcelona Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain WCLC 2025 Co-Chair Dr. Jacob Sands Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about highlights from the conference with Dr. Huijuan Wang and Dr. Lin Wu. Guests: Dr. Chunxia Su Professor of Oncology at Tongji University Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital Dr. Huijuan Wang Professor of Oncology Department of Medical Oncology The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital Dr. Lin Wu Director, Thoracic Oncology Department II Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 September 2024. In this episode: J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi's MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth. https://scrip.citeline.com/SC150865/Quick-Listen-Scrips-Five-MustKnow-Things Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference. Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC. Guests: Dr. Fiona Hegi-Johnson Radiation Oncologist at the Peter MacCallum Cancer Centre Senior Research Fellow at the University of Melbourne Dr. Xiuning Le, M.D., Ph.D. Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology University of Texas M.D. Anderson Cancer Center Dr. Gerrina Ruiter, M.D., Ph.D. Pulmonologist Specialized in Thoracic Oncology at the Netherlands Cancer Institute Amsterdam, The Netherlands

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Jii Bum (Joy) Lee. Guests: Dr. Chul Kim, MD Associate Professor at Georgetown University with a focus on thoracic oncology Dr. Jeongmin Seo, MD Clinical Assistant Professor at Seoul National University Bundang Hospital with a focus on thoracic oncology Dr. Jii Bum (Joy) Lee, MD, PhD Yonsei Cancer Center, Yonsei University College of Medicine

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference. Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018. Guests: Dr. Tina Cascone Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center in Houston, Texas Dr. Marina Chiara Garassino Director, Thoracic Oncology Program and Professor of Medicine University of Chicago Dr. Matthew Smeltzer Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health University of Memphis Professor Caicun Zhou Chief Physician and Director of the Department of Medical Oncology Tongji University in Shanghai Pulmonary Hospital

Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Conference on Lung Cancer with the meeting's other three co-chairs. Guest: Dr. Linda Martin, Professor of Surgery and Chief of Thoracic Surgery at the University of Virginia. Guest: Dr. Fabio Ynoe de Moraes, Chief of Global Radiation Oncology and Associate Professor of Radiation Oncology at Queen University. Guest: Dr. Sandip Patel, Professor of Medicine and Thoracic Medical Oncologist at the University of California San Diego.

Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier and significantly improve lung cancer mortality. Yet they remain underutilized and are only being used to detect certain types of lung cancer, specifically, smoking-related lung cancer. Guest: Dr. Pan-Chyr Yang is a Professor and former President of National Taiwan University College of Medicine and recipient of the IASLC Joseph W. Cullen Prevention & Early Detection Award at the 2020 WCLC. Guest: Dr. Elaine Shum is an Assistant Professor of Medicine at New York University Grossman School of Medicine and Principle Investigator of the Female Asian Nonsmoker Screening Study (FANSS), for which she received the Distinguished Young Investigator Research Award from the EGFR Resisters Summit.

Me and Jim get chatty on this one. --- Support this podcast: https://podcasters.spotify.com/pod/show/archery/support

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.Launch Date: December 29, 2023Release Date: December 29, 2023Expiration Date: November 30, 2024FACULTY BIOSBenjamin Levy, MDAssociate Professor of OncologyJohns Hopkins MedicineAaron Lisberg, MDAssistant Professor of Clinical MedicineUniversity of California, Los AngelesAlexander Spira, MD, PhD, FACPCo-DirectorVirginia Cancer Specialists Research InstituteThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.Launch Date: December 29, 2023Release Date: December 29, 2023Expiration Date: November 30, 2024FACULTY BIOSBenjamin Levy, MDAssociate Professor of OncologyJohns Hopkins MedicineAaron Lisberg, MDAssistant Professor of Clinical MedicineUniversity of California, Los AngelesAlexander Spira, MD, PhD, FACPCo-DirectorVirginia Cancer Specialists Research InstituteThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.Launch Date: December 29, 2023Release Date: December 29, 2023Expiration Date: November 30, 2024FACULTY BIOSBenjamin Levy, MDAssociate Professor of OncologyJohns Hopkins MedicineAaron Lisberg, MDAssistant Professor of Clinical MedicineUniversity of California, Los AngelesAlexander Spira, MD, PhD, FACPCo-DirectorVirginia Cancer Specialists Research InstituteThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

ASCO and ESMO are done, and soon, 2023 itself will be in the rearview mirror. And yet, there are still conferences happening around the world; yes, we know the World Conference on Lung Cancer occurred before ESMO, but there is such a thing as too much of a good thing. Join Michael and Josh on their latest virtual journey abroad, this time to the equatorial island of Singapore, as they report on two of their favourite studies from WCLC 2023. For those who celebrate, have a Merry Christmas and a happy festive season.Links to studies discussed in this episode (subscription may be required):MARS-2: https://pubmed.ncbi.nlm.nih.gov/32873681/FLAURA2: https://www.nejm.org/doi/full/10.1056/NEJMoa2306434For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode of How This Is Building Me, Drs Camidge and Garon discuss the differences in lung cancer management and drug advancement between the United States and Asia and highlight other topline takeaways from the 2023 WCLC.

In this second installment of the two-part "Best of WCLC 2023" series, Dr. Paul Wheatley-Price continues the conversation with Dr. Cheryl Ho, Medical Oncologist at BC Cancer, and Dr. Jonathan Riess, Professor of Medicine at UC Davis in California, to discuss the highlights of this year's World Conference in Lung Cancer in Singapore. This episode focuses on the outcomes from the MARS 2 study in the UK on surgery in mesothelioma. Listen to Part 1 of the Best in WCLC 2023 Podcast at https://on.soundcloud.com/sntfe

In this episode, Dr. Paul Wheatley-Price sits down with Dr. Cheryl Ho, Medical Oncologist at BC Cancer, and Dr. Jonathan Riess, Professor of Medicine at UC Davis in California, to discuss the highlights of this year's World Conference in Lung Cancer in Singapore. A new wave of drugs for lung cancer, unique screening projects from around the globe, and even some chili crab stories!

Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu wrap up WCLC 2023 in Singapore, discussing the meeting's most impactful research, including MARS2, FLAURA2, TRIDENT, HERTHENA, and TROPION.

MARS 2 in Spanish--Monday WCLC Highlights In this Spanish-language podcast, Lung Cancer Considered Host Dr. Narjust Florez enlists two colleagues to discuss the MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Guests: Dra. Rosanna Ruiz, Oncologo clínico Institutio nacional de enfermedades neoplásicas, Lima, Peru Dr. Ricardo Terra, Cirujano toracico Professor, the cirugia toracica en la universidad de Sao Paolo, Brazil

Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu recap three important sessions from Tuesday, September 12th at the IASLC WCLC 2023: Advocates Unite to Increase Lung Cancer Research Funding An update on the AEGEAN Trial--Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable Long-term Outcomes by Radiation Technique for Locally Advanced Non-Small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years

Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Patient advocate Emi Bossio adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer. Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan. Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute

Sunday highlights from WCLC 2023 include hosts Dr. Narjust Florez and Dr. Stephen Liu discussing two-year data from KRYSTAL-1 with Dr. Shirish Gadgeel; a discussion of the IASLC Language Guide and patient-centered language with noted lung cancer patient advocate Jill Feldman; and six-year follow-up data from CheckMate 227 with Dr. Solange Peters. Panelists: Shirish Gadgeel, MD is the Associate Director of Henry Ford Cancer Institute and the Chief of Division of Hematology/Oncology at Henry Ford Health. He is also Professor of Internal Medicine at Michigan State University. Jill Feldman, Lung Cancer Patient and Advocate, Twitter: Solange Peters, MD, PhD Chair and Professor, Medical Oncology, Full Professor, University Hospital of Lausanne, Lausanne, Switzerland.

From lung cancer in women to gender equity in the healthcare workforce, IASLC is privileged to host HRH Princess Dina Mired of Jordan at the 2023 World Conference on Lung Cancer. In this special episode of Lung Cancer Considered, host Dr. Narjust Florez, IASLC President Dr. Heather Wakelee, and WCLC 2023 co-chair Dr. Fiona Hegi-Johnson discuss global advocacy through a gender equity lens, lessons learned from the field, and how HRH Dina Mired's experience as the mother of a cancer survivor has impacted her work and initiatives globally.

The WCLC podcast is going on a short hiatus. In the meantime, we're still taking coaching clients and have added an option for podcast topic requests. If you're interested in a free session to see if coaching is for you, please visit https://www.whitecoatlifecoach.com/schedule-a-free-consult. If you'd like to submit a podcast topic request, please visit https://www.whitecoatlifecoach.com/podcasttopicrequest. Enjoy the rest of your summer and I will see you in the fall!

WCLC 2023 is a global, multi-disciplinary meeting designed for physicians, nurses, clinicians, researchers, scientists, survivors and advocates. This year, the meeting rotates to Singapore and Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by the meeting's three co-chairs for a wide-ranging interview about how attendees can make the most out of their experience during IASLC's flagship annual conference.

Life after service in the World Church Leadership Council... is that really a thing? Of course it is. Grab a cup and “sit down” with former WCLC members Susan Oxley, Rick Maupin, and Ken McLaughlin, as they talk with host, Carla Long, about where they've been and how that has affected where they are now. Grandchildren, Camp Mindcraft, building projects, lessons learned, and new and different roles in the church are just some of what you'll hear about in this episode of What's Brewing. Host: Carla LongGuests: Susan Oxley, Rick Maupin, and Ken McLaughlinDownload TranscriptThanks for listening to Project Zion Podcast!Follow us on Facebook and Instagram!

It's a wrap! Catch up on key highlights of the IASLC 2022 World Conference on Lung Cancer with Dr. Narjust Florez and Dr. Stephen Liu as they discuss the science, social engagement and notable abstracts with Dr. Ben Levy.

We've approached a remarkable close to the last day of the IASLC 2022 World Conference on Lung Cancer in Vienna, Austria. Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez interview Dr. Belinda King Kallimanis, Dr. Charles Rudin and Dr. Solange Peters about patient-centric clinical trial consent forms, an update on the Keynote 604 trial, the importance of women's sexual health and new data on a combination of therapies for patients with KRAS mutations.

Destacados Diarios WCLC 2022 - 8 de Agosto Es el tercer día de la Conferencia Mundial IASLC 2022 sobre Cáncer de Pulmón! La Dra. Narjust Florez recibe a dos investigadores fundamentales: El Dr. Mariano Provencio y La Dra. Enriqueta Felip, para discutir sus estudios mejor calificados.

It's Day 3 at the IASLC 2022 World Conference on Lung Cancer! Dr. Narjust Florez hosts pivotal researchers Dr. Enriqueta Felip, Dr. Mariano Provencio, and Dr. Rachael Murray to discuss their top-rated studies. IASLC President Dr. Heather Wakelee also joins in to give insight on how the committee selected these high-ranked abstracts for this year's Presidential Symposium.